KALA BIO, Inc.
KALA BIO, Inc. a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of therapies for rare and severe eye diseases. The company's lead product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects; and limbal stem cell deficiency and other rare corneal diseases. Its preclinical d… Read more
KALA BIO, Inc. (0JQ2) - Total Assets
Latest total assets as of September 2025: $25.02 Million USD
Based on the latest financial reports, KALA BIO, Inc. (0JQ2) holds total assets worth $25.02 Million USD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
KALA BIO, Inc. - Total Assets Trend (2013–2024)
This chart illustrates how KALA BIO, Inc.’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
KALA BIO, Inc. - Asset Composition Analysis
Current Asset Composition (December 2024)
KALA BIO, Inc.'s total assets of $25.02 Million consist of 95.2% current assets and 4.8% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 92.3% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2013–2024)
This chart illustrates how KALA BIO, Inc.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: KALA BIO, Inc.'s current assets represent 95.2% of total assets in 2024, an increase from 84.4% in 2013.
- Cash Position: Cash and equivalents constituted 92.3% of total assets in 2024, up from 75.5% in 2013.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2013.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
KALA BIO, Inc. Competitors by Total Assets
Key competitors of KALA BIO, Inc. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
| No similar companies found. | ||
KALA BIO, Inc. - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - KALA BIO, Inc. generates 0.04x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - KALA BIO, Inc. is currently not profitable relative to its asset base.
KALA BIO, Inc. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.75 | 2.15 | 7.71 |
| Quick Ratio | 0.75 | 2.15 | 7.48 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-8.30 Million | $ 27.41 Million | $ 149.15 Million |
KALA BIO, Inc. - Advanced Valuation Insights
This section examines the relationship between KALA BIO, Inc.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | - |
| Latest Market Cap to Assets Ratio | 0.04 |
| Asset Growth Rate (YoY) | -0.8% |
| Total Assets | $55.48 Million |
| Market Capitalization | $1.97 Million USD |
Valuation Analysis
Below Book Valuation: The market values KALA BIO, Inc.'s assets below their book value (0.04 x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: KALA BIO, Inc.'s assets decreased by 0.8% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for KALA BIO, Inc. (2013–2024)
The table below shows the annual total assets of KALA BIO, Inc. from 2013 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $55.48 Million | -0.83% |
| 2023-12-31 | $55.95 Million | -35.56% |
| 2022-12-31 | $86.82 Million | -37.73% |
| 2021-12-31 | $139.43 Million | -37.08% |
| 2020-12-31 | $221.61 Million | +43.60% |
| 2019-12-31 | $154.32 Million | -30.16% |
| 2018-12-31 | $220.97 Million | +90.27% |
| 2017-12-31 | $116.13 Million | +150.67% |
| 2016-12-31 | $46.33 Million | +448.40% |
| 2015-12-31 | $8.45 Million | -27.93% |
| 2014-12-31 | $11.72 Million | +65.75% |
| 2013-12-31 | $7.07 Million | -- |